actiq 1600 mikrogram sugetabletter
teva pharma b.v. - fentanylcitrat - sugetabletter - 1600 mikrogram
abstral 200 mikrogram resoribletter, sublinguale
paranova danmark a/s - fentanylcitrat - resoribletter, sublinguale - 200 mikrogram
abstral 200 mikrogram resoribletter, sublinguale
orifarm a/s - fentanylcitrat - resoribletter, sublinguale - 200 mikrogram
actiq 400 mikrogram sugetabletter
teva pharma b.v. - fentanylcitrat - sugetabletter - 400 mikrogram
actiq 600 mikrogram sugetabletter
teva pharma b.v. - fentanylcitrat - sugetabletter - 600 mikrogram
actiq 800 mikrogram sugetabletter
teva pharma b.v. - fentanylcitrat - sugetabletter - 800 mikrogram
abstral 200 mikrogram resoribletter, sublinguale
2care4 aps - fentanylcitrat - resoribletter, sublinguale - 200 mikrogram
abstral 400 mikrogram resoribletter, sublinguale
2care4 aps - fentanylcitrat - resoribletter, sublinguale - 400 mikrogram
actiq 600 mikrogram sugetabletter
paranova danmark a/s - fentanylcitrat - sugetabletter - 600 mikrogram
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.